Applied Therapeutics (APLT) surged 13.30% intraday following positive developments in its regulatory and clinical progress. Recent news highlighted a meeting with the FDA, which could reshape its rare disease pipeline, and the presentation of full 12-month clinical results from the INSPIRE Phase 2/3 trial of govorestat for.
Comments
No comments yet